Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance.
Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance.
复制标题
DOI：
10.7150/jca.24872
复制
发表时间：
2018
影响因子：
3.9
通讯作者：
Cao X
中科院分区：
文献类型：
--
作者：
Lin L;Zhao J;Hu J;Zou G;Huang F;Han J;He Y;Cao X
目的：本研究的目的是探讨吸烟史对无EGFR突变和ALK重排的晚期非鳞状细胞肺癌患者持续维持性治疗的预测价值。方法：对71例连续接受培美曲塞持续维持治疗2个周期以上的EGFR和ALK阴性的晚期非鳞状细胞肺癌患者进行回顾性分析。根据吸烟史将入选患者分为从未吸烟者和现在吸烟者两组。结果：71例非鳞状细胞肺癌患者中，有30例(42.3%)为从未吸烟者，41例(57.7%)为现吸烟者。从未/曾经轻度吸烟者的客观有效率显著高于现在吸烟者(26.7%vs.7.3%，p=0.026)。无进展生存期(6.6[95%CI 5.3~7.9]个月比5.1[95%CI 3.5~6.7]个月；HR：0.557，95%CI 0.339~0.915，p=0.021)和总生存期(OS)(17.3[95%CI 14.4~20.2]个月vs 15.7[95%CI 12.0~19.4]个月；HR：0.578，95%CI 0.338-0.986，P=0.044)。多因素分析表明，吸烟史是PFS和OS的独立预测因素。结论：在没有EGFR突变和ALK重排的晚期非鳞状NSCLC患者中，当前吸烟是培美曲塞持续维持治疗的一个独立的负面预测因素。
Objectives: The aim of this study is to investigate the predictive value of smoking history on treatment outcomes of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC patients without EGFR mutations and ALK rearrangements. Methods: 71 consecutive EGFR and ALK negative advanced non-squamous NSCLC patients who had received pemetrexed continuation maintenance therapy at least two cycles were retrospectively analyzed in our single center. The enrolled patients were categorized into two groups as never-/former light smokers and current smokers according to their smoking history. Results: In the 71 non-squamous NSCLC patients, 30 (42.3%) were never-/former light smokers and 41 (57.7%) were current smokers. The objective response rate (ORR) of never-/former light smokers was significantly higher than that of current smokers (26.7% vs. 7.3%, p = 0.026). Never-/former light smokers showed significantly longer progression free survival (PFS) (6.6 [95% CI 5.3-7.9] months vs. 5.1 [95% CI 3.5-6.7] months; HR: 0.557, 95% CI 0.339-0.915, p = 0.021) and overall survival (OS) (17.3 [95% CI 14.4-20.2] months vs. 15.7 [95% CI 12.0-19.4] months; HR: 0.578, 95% CI 0.338-0.986, p = 0.044) than current smokers. Multivariate analysis identified smoking history was an independent predictive factor for PFS and OS. Conclusions: Current smoking is an independent negative predictive factor of outcomes for pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC patients without EGFR mutations and ALK rearrangements.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
45.3
作者：
Scagliotti, Giorgio Vittorio;Parikh, Purvish;Gandara, David
通讯作者：
Gandara, David
影响因子：
51.1
作者：
Paz-Ares, Luis;de Marinis, Filippo;Gridelli, Cesare
通讯作者：
Gridelli, Cesare
影响因子：
5.3
作者：
Khuder, SA
通讯作者：
Khuder, SA
影响因子：
20.4
作者：
Maus, Martin K. H.;Mack, Philip C.;Gandara, David R.
通讯作者：
Gandara, David R.